secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001787306-23-000076
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q2 2023: ZORYVE revenue $4.8M (+72% QoQ); net loss $71M
---------------------------------------------------------------

- Total revenues $5.2M; ZORYVE net product revenue $4.8M, up 72% sequentially.
- Net loss $71.0M ($1.16 per share) vs $67.4M ($1.31) in Q2 2022.
- Cash and marketable securities $269.6M as of June 30 vs $410.8M at Dec 31, 2022.
- Commercial coverage expanded to >130M lives (all 3 largest PBMs) for ZORYVE.
- FDA action date Dec 16, 2023 for roflumilast foam in seborrheic dermatitis; sNDA for atopic dermatitis expected late Q3/early Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000076/0001787306-23-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000076/arqt-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001787306-23-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer